Literature DB >> 19695683

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.

Simone Muenst1, Sylvia Hoeller, Stephan Dirnhofer, Alexandar Tzankov.   

Abstract

Programmed death-1 (PD-1), a protein that is physiologically expressed by germinal center-associated helper T cells, has an inhibitory function on T-cell activity. The distribution of PD-1+ lymphocytes in the microenvironment of Hodgkin lymphoma is not random and can serve as a diagnostic marker. We measured the number of PD-1+ lymphocytes in Hodgkin lymphoma and correlated it with the remaining background lymphocyte populations and known biological and clinical key data on a tissue microarray platform encompassing 280 cases of classical Hodgkin lymphoma and 3 cases of nodular lymphocyte-predominant Hodgkin lymphoma. Prognostic cutoff scores were determined by receiver operating curve analysis. The number of PD-1+ tumor-infiltrating lymphocytes in 189 evaluable cases was median of 27 and mean of 269 cells/mm(2), being higher in lymphocyte-rich classical Hodgkin lymphoma and lower in the mixed cellularity variant. Rimming of tumor cells by PD-1+ cells was observed in all cases of nodular lymphocyte-predominant Hodgkin lymphoma but only in 1% of classical Hodgkin lymphomas, particularly in lymphocyte-rich and -mixed cellularity variants. Thus, the presence of PD-1+ rosettes around neoplastic cells is typical but not exclusive for nodular lymphocyte-predominant Hodgkin lymphoma because it may be encountered in classical Hodgkin lymphoma. The PD-1+ cell amount was lower in classical Hodgkin lymphoma cases with 9p24 gains (PD-1 ligand 2 locus) and in cases with higher numbers of FOXP3+ regulatory T cells. An increased amount of PD-1+ tumor-infiltrating lymphocytes above the prognostic cutoff score (23 cells/mm(2)) was a stage-independent negative prognostic factor of overall survival as opposed to the number of FOXP3+ regulatory T cells. Along with the latter, PD-1+ cells might represent important lymphoma/host microenvironment modulators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695683     DOI: 10.1016/j.humpath.2009.03.025

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  49 in total

1.  Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

Authors:  Yuki Honda; Atsushi Otsuka; Sachiko Ono; Yosuke Yamamoto; Judith A Seidel; Satoshi Morita; Masahiro Hirata; Tatsuki R Kataoka; Tatsuya Takenouchi; Kazuyasu Fujii; Takuro Kanekura; Yuko Okubo; Kenzo Takahashi; Teruki Yanagi; Daichi Hoshina; Hiroo Hata; Riichiro Abe; Taku Fujimura; Takeru Funakoshi; Koji Yoshino; Mamiko Masuzawa; Yasuyuki Amoh; Ryota Tanaka; Yasuhiro Fujisawa; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-11-04       Impact factor: 8.110

Review 2.  Follicular helper T cells: implications in neoplastic hematopathology.

Authors:  Philippe Gaulard; Laurence de Leval
Journal:  Semin Diagn Pathol       Date:  2011-08       Impact factor: 3.464

3.  Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.

Authors:  Janice S Ahn; Ali Al-Habib; Jeffrey A Vos; Aliyah R Sohani; Oralia Barboza-Quintana; Juan P Flores; Sijin Wen; Flavia G Rosado
Journal:  Ann Clin Lab Sci       Date:  2020-03       Impact factor: 1.256

4.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

5.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

Review 6.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

Review 7.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to November 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-12-17       Impact factor: 0.196

9.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

10.  The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus Kröger; Ilya Kazantsev; Tatjana Zabelina; Francis Ayuk; Axel Rolf Zander
Journal:  Adv Hematol       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.